Analysts’ Recent Ratings Updates for 10x Genomics (TXG)

A number of firms have modified their ratings and price targets on shares of 10x Genomics (NASDAQ: TXG) recently:

• 7/9/2026 – 10x Genomics had its price target raised by Morgan Stanley from $22.00 to $37.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $24.00 to $45.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – 10x Genomics had its price target raised by Piper Sandler from $20.00 to $42.00. They now have a “neutral” rating on the stock.
• 6/24/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – 10x Genomics had its price target raised by Barclays PLC from $30.00 to $40.00. They now have an “overweight” rating on the stock.
• 5/18/2026 – 10x Genomics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 5/12/2026 – 10x Genomics had its price target raised by Morgan Stanley from $20.00 to $22.00. They now have an “equal weight” rating on the stock.
• 5/12/2026 – 10x Genomics had its price target raised by JPMorgan Chase & Co. from $17.00 to $20.00. They now have a “neutral” rating on the stock.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 30,000 shares of 10x Genomics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the transaction, the chief executive officer directly owned 1,108,380 shares in the company, valued at approximately $38,172,607.20. This trade represents a 2.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 11,595 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $283,381.80. Following the completion of the sale, the insider directly owned 502,000 shares in the company, valued at $12,268,880. This represents a 2.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 96,309 shares of company stock valued at $2,704,157 over the last quarter. Corporate insiders own 8.84% of the company’s stock.

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.